# Bariatric Surgery With or Without Concomitant Laparoscopic Cholecystectomy in Morbidly Obese Patients With Gallbladder Stone Disease: A Prospective Randomized Controlled Pilot Study

**Authors:** Mohamed Atteya Heikal, Ahmed Mohamed Reda Negm, Hosam Mohamed Elghadban, Mahmoud A. Aziz

PMC · DOI: 10.1155/jobe/6054585 · Journal of Obesity · 2026-02-26

## TL;DR

This study compares removing the gallbladder during bariatric surgery versus delaying it, finding that doing both at once is safe and reduces future complications.

## Contribution

The study provides randomized evidence supporting the safety and benefits of combining gallbladder removal with bariatric surgery in morbidly obese patients.

## Key findings

- Concomitant laparoscopic cholecystectomy during bariatric surgery is safe and feasible.
- 79.3% of patients who delayed cholecystectomy developed symptomatic gallstones later.
- Operative time was longer but postoperative complications were similar between groups.

## Abstract

Imagine a surgeon’s critical decision: Should the gallbladder be removed now, along with the planned bariatric surgery, or risk the complication and necessity of a second surgery later? This clinical dilemma is central to treating morbidly obese patients, who face a high prevalence of gallstone disease exacerbated by rapid postoperative weight loss. The best approach to managing existing gallstones in bariatric candidates remains debated, with debate focusing on whether combining laparoscopic cholecystectomy (LC) with bariatric surgery is both safe and advantageous. In this pilot study, we provide randomized evidence to guide this decision.

In this prospective randomized controlled pilot study, 58 morbidly obese patients with ultrasound‐confirmed gallstones were randomly assigned to two groups: Group I (n = 30) received bariatric surgery and LC; Group II (n = 28) had bariatric surgery only, with LC delayed for symptoms. The primary outcomes were clearly defined as operative time, intraoperative complications, and postoperative morbidity, providing a focused measure of safety and efficacy. Secondary outcomes included hospital stay, pain, and follow‐up gallstone symptoms.

Baseline demographics and comorbidities were similar across groups. Operative time was longer in Group I (98.93 ± 11.58 min) than in Group II (75.18 ± 11.26 min, p < 0.001). An extra port was used in 20% of Group I patients, compared with none in Group II (p = 0.012). No significant differences were observed in bleeding, bile leakage, postoperative complications, or hospital stay. Group I reported higher pain scores (p < 0.001). During follow‐up, 79.3% of Group II developed symptomatic gallstones, requiring later cholecystectomy.

Concomitant LC during bariatric surgery in morbidly obese patients with pre‐existing gallstones is demonstrated to be safe and feasible, with acceptable increases in operative time and postoperative pain. The high rate (79.3%) of symptomatic gallstone development in patients who did not undergo concomitant cholecystectomy supports adopting routine concomitant LC to prevent future morbidity, thereby influencing clinical decision‐making and standard practice.

Trial Registration: ClinicalTrials.gov: NCT04567890

## Linked entities

- **Diseases:** morbid obesity (MONDO:0005139)

## Full-text entities

- **Genes:** mucin [NCBI Gene 100508689]
- **Diseases:** cholangitis (MESH:D002761), bile duct (MESH:D001649), BS (MESH:D001816), vomiting (MESH:D014839), Gallstone Disease (MESH:D002769), biliary colic (MESH:D003085), obstructive jaundice (MESH:D041781), dyspepsia (MESH:D004415), fever (MESH:D005334), pulmonary embolism (MESH:D011655), jaundice (MESH:D007565), thromboembolic (MESH:D013923), splenic injuries (MESH:D013158), cholecystitis (MESH:D002764), obstructive sleep apnea (MESH:D020181), Type 2 diabetes mellitus (MESH:D003924), nausea/vomiting (MESH:D020250), nausea (MESH:D009325), Gallbladder polyps (MESH:D011127), Obese (MESH:D009765), bleeding (MESH:D006470), wound infection (MESH:D014946), dehydration (MESH:D003681), stone (MESH:D007669), deep vein thrombosis (MESH:D020246), vascular injuries (MESH:D057772), leak (MESH:D019559), urinary tract infection (MESH:D014552), Weight Loss (MESH:D015431), abdominal pain (MESH:D015746), Pneumoperitoneum (MESH:D011027), LC (MESH:D017562), leukocytosis (MESH:D007964), acute pancreatitis (MESH:D010195), Blood Loss (MESH:D016063), acute cholecystitis (MESH:D041881), infection (MESH:D007239), dilated (MESH:D002311), pulmonary complications (MESH:D008171), Postoperative Complications (MESH:D011183), cancer (MESH:D009369), Postoperative Pain (MESH:D010149), Gallstone (MESH:D042882), choledocholithiasis (MESH:D042883), Pain (MESH:D010146), hypertension (MESH:D006973), adhesions (MESH:D000267), dyslipidemia (MESH:D050171), intra-abdominal abscess (MESH:D018784), bile leakage (MESH:D003763), GERD (MESH:D005764), bowel injuries (MESH:D012778), trauma (MESH:D014947), atelectasis (MESH:D001261), complication (MESH:D008107), Gallbladder Stone Disease (MESH:D005705)
- **Chemicals:** cholesterol (MESH:D002784), low-molecular-weight heparin (MESH:D006495), silicone (MESH:D012828), lipid (MESH:D008055), methylene blue (MESH:D008751), UDCA (MESH:D014580), cephalosporin (MESH:D002511), acetaminophen (MESH:D000082), Roux-en (-), olive oil (MESH:D000069463)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12945468/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12945468/full.md

## References

22 references — full list in the complete paper: https://tomesphere.com/paper/PMC12945468/full.md

---
Source: https://tomesphere.com/paper/PMC12945468